Dennis M. Lanfear - 23 Jan 2026 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)

Role
President & CEO, Director
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear
Issuer symbol
CHRS
Transactions as of
23 Jan 2026
Net transactions value
$0
Form type
4
Filing time
26 Jan 2026, 16:40:58 UTC
Previous filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lanfear Dennis M President & CEO, Director C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY /s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear 26 Jan 2026 0001420822

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Award $0 +375,000 +56% $0.000000 1,048,235 23 Jan 2026 Direct F1
holding CHRS Common Stock 432,684 23 Jan 2026 By Trust F2
holding CHRS Common Stock 86,965 23 Jan 2026 By LLC F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +750,000 $0.000000 750,000 23 Jan 2026 Common Stock 750,000 $2.06 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F3 These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F4 The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 23, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.